ISRCTN10401455已完成未知
Establish and analyse the safety and efficacy of an integrated care model for the management of patients receiving oral anti-cancer agents in the community by an Advanced Nurse Practitioner (ANP): a pilot study
Irish Cancer Society0 个研究点目标入组 37 人开始时间: 2020年11月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 37
研究概览
简要总结
2022 Preprint results in https://doi.org/10.1101/2022.02.23.22271044 Results of phase I and protocol for phase II (added 23/09/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36259243/ Qualitative study (added 20/10/2022) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38424625/ (added 01/03/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Currently receiving an oral anti-cancer treatment
- •2. Have received OAM within 6 months of data collection commencing
- •3. Aged 18 years and over
- •4. Cognitively able to provide informed consent and complete the study activities
- •5. An ECOG performance status of 0-2
排除标准
- •1. Refusal to participate
- •2. Patients not taking oral anticancer medication.
研究者
相似试验
已完成
1 期
A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) in relapsed/refractory cancers of children and young adultsCancerISRCTN21727048niversity of Birmingham49
进行中（未招募）
1 期
A phase I/II study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteersCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN15281137niversity of Oxford1,077
招募中
1 期
A Phase I/II study to assess the safety and efficacy of full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) in the treatment of Rett syndrome (RTT)Rett SyndromeNeurological - Neurodegenerative diseasesACTRN12623000563662Fenix Innovation Group14
尚未招募
1 期
CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut SyndromeLennox-Gastaut Syndrome (LGS)Dravet Syndrome (DS)NCT06738732Alexander Rotenberg25
进行中（未招募）
1 期
Phase I/II Study of MK-3475 in Combination with Trametinib and Dabrafenibadvanced or metastatic melanoma - all parts of the trialadvanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2015-000681-55-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.190